Drug Controller General Of India, Surinder Singh, On India’s Regulatory Overhaul: An Interview With PharmAsia News
This article was originally published in The Pink Sheet Daily
Singh recounts steps toward Indian first-in-human drug trials.
You may also be interested in...
India’s Drug Watchdog DCGI Speeds Up Regulatory Overhaul; Single Window Clearance to Precede Central Drug Authority
MUMBAI - India's drug regulatory body, the Drug Controller General of India, is set for a comprehensive overhaul of its regulatory and administrative functions
Sweeping Changes In India’s Clinical Trial Laws Could Allow Phase I MNC Studies Under Certain Circumstances
MUMBAI - Conducting clinical trials in India may get a little easier for multinational drug companies. That is because the much-awaited amendments to the contentious "Schedule Y" of India's Drug and Cosmetics Act have moved one step forward
MUMBAI - The long drawn patent fight in India between Swiss drug giant Roche and Indian generics company Cipla over lung cancer drug Tarceva (erlotinib) is poised for an interesting turn